ADCs are composed of a humanized monoclonal antibody specific for a tumor surface antigen such as HER2, a cleavable or uncleavable linker, and a cytotoxic payload; they thus enable a more targeted delivery of tumor-directed therapy, while minimizing toxicity to normal tissues and thus fewer adverse effects than traditional chemotherapy [33]. Here, ERBB2 is linked to neoplasm.